Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
March 31, 2025 16:01 ET | Source: Celcuity Inc.

Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging...
March 24, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call

MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
March 20, 2025 08:00 ET | Source: Pathos AI

Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor

CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced...
February 25, 2025 16:15 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first...
February 25, 2025 07:05 ET | Source: Celcuity Inc.

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
February 25, 2025 05:00 ET | Source: Orion Oyj

Orion Group Financial Statement Release January–December 2024

ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2024 25 FEBRUARY 2025 at 12:00 EET Orion Group Financial Statement Release January–December 2024 Net sales totalled EUR 1,542.4 (January–December...
February 18, 2025 16:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered...
January 13, 2025 08:05 ET | Source: ORIC Pharmaceuticals

ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration...
January 07, 2025 02:00 ET | Source: Orion Oyj

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

ORION CORPORATION INVESTOR NEWS 7 JANUARY 2025 at 9:00 EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration...